About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diabetes Clinical Trials in Pennsylvania | 495 Studies | Clareo Health

Clinical Trials DiabetesPennsylvania

Diabetes Clinical Trials in Pennsylvania

Find 495 clinical trials for diabetes near Pennsylvania. Connect with research centers in your area.

All Diabetes trials nationwide All trials in Pennsylvania

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 201-220 of 495 trials

TERMINATEDNA50 miles

A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial

NCT02409017

To assess which of two commonly utilized insulin drip protocols has better outcomes when used during the labor process.

DiabetesPregnancy

WellSpan Health20 participantsStarted Apr 2015

York, Pennsylvania, United States

COMPLETEDPhase 474 miles

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

NCT01864174

The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy

Type 2 Diabetes Mellitus

Bristol-Myers Squibb1,736 participantsStarted Jun 2013

Birmingham, Alabama, United States • Muscle Shoals, Alabama, United States • Mesa, Arizona, United States +153 more locations

Diabetes Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 374 miles

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S1,201 participantsStarted Jan 2016

Tuscumbia, Alabama, United States • Chandler, Arizona, United States • Phoenix, Arizona, United States +206 more locations

COMPLETEDPhase 389 miles

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

NCT00157339

Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.

Diabetes MellitusAsthmaPulmonary Disease, Chronic Obstructive

Eli Lilly and Company299 participantsStarted Aug 2005

Montgomery, Alabama, United States • Burbank, California, United States • Greenbrae, California, United States +98 more locations

COMPLETEDPhase 289 miles

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S706 participantsStarted Sep 2015

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Coronado, California, United States +147 more locations

COMPLETEDPhase 395 miles

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941

This Phase 3 study was intended to demonstrate superiority of either sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult participants with type 1 diabetes mellitus (T1D) who have inadequate glycemic control with insulin therapy.

Type 1 Diabetes Mellitus

Lexicon Pharmaceuticals793 participantsStarted Mar 2015

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Escondido, California, United States +72 more locations

COMPLETEDPhase 395 miles

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

NCT03136484

This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S788 participantsStarted Mar 2017

Anaheim, California, United States • La Mesa, California, United States • Los Angeles, California, United States +116 more locations

COMPLETEDPhase 395 miles

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Diabetes Mellitus, Type 2Diabetic Nephropathy

Janssen Research & Development, LLC4,401 participantsStarted Feb 2014

Birmingham, Alabama, United States • Montgomery, Alabama, United States • Tempe, Arizona, United States +572 more locations

COMPLETEDPhase 395 miles

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

NCT02402933

Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.

HypoglycemiaDiabetes Mellitus

Eli Lilly and Company26 participantsStarted Mar 2015

Tallahassee, Florida, United States • Baltimore, Maryland, United States • Waltham, Massachusetts, United States

COMPLETEDPhase 399 miles

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

NCT02825251

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes.

DiabetesDiabetes Mellitus, Type 1

Novo Nordisk A/S472 participantsStarted Jul 2016

Encino, California, United States • Fresno, California, United States • Roseville, California, United States +89 more locations

COMPLETEDPhase 2104 miles

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

NCT02459899

The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.

Type 1 Diabetes Mellitus

Lexicon Pharmaceuticals141 participantsStarted Jul 2015

Concord, California, United States • Ventura, California, United States • Denver, Colorado, United States +14 more locations

COMPLETEDPhase 3109 miles

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

NCT02906917

Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S532 participantsStarted Sep 2016

Glendale, Arizona, United States • Phoenix, Arizona, United States • Anaheim, California, United States +68 more locations

COMPLETEDPhase 2117 miles

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01781975

Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia with current technology, and thus they are at risk for devastating long-term complications. This phase II study is designed to evaluate the safety and efficacy of imatinib mesylate as a novel therapy for new-onset T1DM. Imatinib is a first-in-class tyrosine kinase inhibitor. This study will explore the potential role of short-term therapy with imatinib to induce tolerance and possibly lead to a durable long-term remission of T1DM.

Diabetes Mellitus, Type IDiabetes Mellitus, Insulin-Dependent, 1Type 1 Diabetes Mellitus+2 more

University of California, San Francisco67 participantsStarted Jan 2014

San Francisco, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +6 more locations

COMPLETEDPhase 3117 miles

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178

The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.

Type 2 DiabetesChronic Kidney Disease

Eli Lilly and Company577 participantsStarted Jul 2012

Montgomery, Alabama, United States • Azusa, California, United States • Granada Hills, California, United States +86 more locations

COMPLETEDPhase 3117 miles

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

NCT00355849

A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder \[also known as AIR® Inhaled Insulin\]\[AIR® is a registered trademark of Alkermes,Inc.\] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily insulin glargine injections.

Diabetes Mellitus, Type 2

Eli Lilly and Company555 participantsStarted Aug 2006

Fresno, California, United States • Pomona, California, United States • West Palm Beach, Florida, United States +66 more locations

COMPLETEDPhase 2/3117 miles

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935

The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)

Type 2 Diabetes Mellitus, CKD and Albuminuria

AstraZeneca459 participantsStarted Sep 2015

Peoria, Arizona, United States • Chula Vista, California, United States • Concord, California, United States +109 more locations

COMPLETEDPhase 3243 miles

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072

This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime clinical research center (CRC) visits with random assignment to receive G-Pen™ glucagon 1 mg during one period and Lilly Glucagon 1 mg during the other. Each daytime visit is preceded by an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is brought into a state of hypoglycemia through IV administration of regular insulin diluted in normal saline. After a hypoglycemic state with plasma glucose \< 50 mg/dL is verified, the subject is administered a dose of G-Pen or Lilly Glucagon via subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes post-dosing, with a value of \>70.0 mg/dL within 30 minutes of glucagon administration indicating a positive response. After 3 hours, the subject is given a meal and discharged when medically stable. After a wash-out period of 7 to 28 days, subjects return to the CRC, and the procedure are repeated with each subject crossed over to the other treatment. A follow-up visit as a safety check is conducted 2-7 days following administration of the final dose of study drug.

Insulin HypoglycemiaType 1 Diabetes MellitusSevere Hypoglycemia

Xeris Pharmaceuticals81 participantsStarted Jan 2018

Chula Vista, California, United States • Walnut Creek, California, United States • Atlanta, Georgia, United States +3 more locations

COMPLETEDNA1157 miles

Incentivized Smoking Cessation for Diabetics

NCT03527667

This pilot study aims to test the feasibility of providing incentives to patients with T2D contingent on remote biochemical verification using a smartphone carbon monoxide (CO) monitor. The investigators will use an ecological momentary assessment (EMA) smartphone application and CO sensor to monitor urges to smoke, stressors, smoking behaviors, and to validate continuous abstinence throughout the intervention. Two different contingency management structures will be explored to investigate the length of time incentives need to be offered.

Smoking CessationDiabetes Mellitus, Type 2

University of Oklahoma19 participantsStarted Jun 2018

Oklahoma City, Oklahoma, United States • Glasgow, Scotland, United Kingdom

COMPLETEDPhase 31679 miles

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

NCT01648582

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.

Type 2 Diabetes Mellitus

Eli Lilly and Company774 participantsStarted Jul 2012

Beijing, China • Changsha, China • Chengdu, China +27 more locations

COMPLETEDPhase 32258 miles

A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes

NCT02132637

The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.

Type 2 Diabetes Mellitus

Eli Lilly and Company68 participantsStarted May 2014

Chula Vista, California, United States • Mainz, Germany • Neuss, Germany

PreviousPage 11 of 25Next

Other Conditions in Pennsylvania

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia